CASE REPORT

The case of double primary lung adenocarcinomas with an EGFR mutation and ALK translocation successfully treated with alectinib at the post-surgical recurrence

Yoshio Tsunezuka1, Nobuyoshi Tanaka1, Hideki Fujimori1, Yuki Togashi2, Satoko Baba1, Kengo Takeuchi1, Kazuyoshi Katayanagi1, Hiroshi Kurumaya1, Hironori Kitade4, Shinji Atagi5, and Seiji Yano4,6

1Department of General Thoracic Surgery, Ishikawa Prefectural Central Hospital, Kanazawa, Japan, 2Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan, 3Department of Pathology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan, 4Chemotherapy Center, Houju Memorial Hospital, Nomi, Japan, 5Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan, 6Department of Medical Oncology, Kanazawa University Cancer Research Institute, Kanazawa University, Kanazawa, Japan

Abstract: A 36-year-old male was found two nodules in the right lower lobe of the lung. After the surgical resection, both lesions were diagnosed as invasive adenocarcinomas. One lesion was primarily lepidic growth component with EGFR-L858R mutation, and the other was micropapillary component with ALK translocation accompanying mediastinal lymphnode metastases. While he experienced disease recurrence, the disease was controlled by an ALK inhibitor, given based on the findings of surgical specimens. This is the first case who had two simultaneous lung cancers with EGFR mutation and ALK translocation in each respective lesion, and was successfully treated with ALK inhibitor at the post-surgical recurrence. J. Med. Invest. 64 : 305-307, August, 2017

Keywords: EGFR mutation, EML4-ALK, double cancers, alectinib

INTRODUCTION

Mutated EGFR and translocations in ALK are major drug targets in non-small cell lung cancer (NSCLC). In general, these two oncogenic drivers exist exclusively (1). Here we present to the best of our knowledge the first patient who had two simultaneous lung cancers with EGFR mutation and ALK translocation in each respective lesion, and was successfully treated with ALK inhibitor alectinib at the post-surgical recurrence.

CASE REPORT

A 36-year-old male, who was 8-pack year current smoker with no significant previous medical history, was found to have right lung opacity on a chest radiograph during a health examination. A computed tomography chest scan revealed two nodules in the right lower lobe, a 2.6 cm lesion in S8/9 with a cavity and ground glass opacity, and a solid and lobulated 2.1 cm lesion in S9. The maximum standard uptake value (SUVmax) of S8/9 and S9 lesions by FDG-PET scan was 1.9 and 15.3, respectively (Fig. 1). No significant accumulation was detected elsewhere. Each lesion was diagnosed as cT1bN0M0 (cStage IA) and a right lower lobectomy with mediastinal lymphadenectomy was performed. Histological examination revealed the right S8/9 lesion to be invasive adenocarcinoma primarily with a lepidic growth component and the S9 lesion as invasive papillary adenocarcinoma with a micropapillary component. Mediastinal (#7, 4/6) and right hilar lymph node (#11, 1/6) metastases were detected.

Received for publication February 19, 2017 ; accepted April 14, 2017.
Address correspondence and reprint requests to Seiji Yano, MD, PhD, Department of Medical Oncology, Cancer Research Institute, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa 920-0934, Japan and Fax : +81-76-234-4524.

Figure 1. Radiographical appearance of the two lung lesions. (A) Chest radiograph showing the opacity in the right lower field. (B) Chest CT scan showing right lung lesion in S8/9. (C) Chest CT scan showing right lung lesions in S9. (D) FDG-PET scan showing low accumulation in the S8/9 lesion. (E) FDG-PET scan showing high accumulation in the S9 lesion.
An EGFR-L858R mutation was detected by PCR-Invader assay in the S8/9, but not S9 lesion. FISH analyses for ALK and EML4 revealed that cells from the S9, but not S8/9 lesion, had an EML4-ALK fusion (Fig. 2). Analysis with 5’-RACE using corresponding formalin-fixed paraffin-embedded tissue (2) further revealed the S9 tumor to have EML4-ALK E13; A20 (variant 1). Immunohistochemistry with specific antibodies for L858R mutant EGFR, and ALK showed that the S8/9, but not S9 lesion, was positive for EGFR-L858R. The S9, but not S8/9 lesion, was positive for ALK (Fig. 3), consistent with genetic results. Mediastinal and right hilar lymph node metastases were positive for ALK, but not EGFR-L858R (Fig. 3).

Therefore, we diagnosed that this patient had double lung cancers consisting of an EGFR-L858R mutation positive lesion (pT1bN0 M0, pStage IA) and an EML4-ALK translocation positive lesion (pT2aN2M0, pStage IIIA). Treatment with adjuvant chemotherapy consisting of 4 cycles of cisplatin and vinorelbine was given. Ten months after the completion of the adjuvant chemotherapy, the multiple bone metastases, associated with small volume of right pleural effusion, pericardial effusion, and elevated level of serum carcinoembryonic antigen (CEA), were detected by FDG-PET scan (Fig. 4). Re-biopsy could not be performed because there were no lesions for safe biopsy. We diagnosed the patient had recurrence of EML4-ALK lung cancer component, since EML4-ALK positive tumor cells invaded the mediastinal and right hilar lymph nodes.

The patient was treated with an ALK inhibitor alectinib (300 mg twice a day) (3). FDG-PET and CT scan taken 3 months after the initiation of alectinib revealed that accumulation in multiple bone lesions, right pleural effusion, and pericardial effusion disappeared (Fig. 4). Elevated level of CEA was improved with in normal limit by the treatment. Alectinib treatment is continued for longer than 17 months.

Figure 2. Detection of EML4-ALK in tumor cells in the S9 lesion. (A) FISH analyses for ALK and EML4 revealed tumor cells in the S9 lesion, but not the S8/9 lesion, had an EML4-ALK fusion gene (5’-ALK, red; 3’-ALK, green; EML4, blue). Arrowheads indicate the rearranged EML4-ALK allele. (B) Sequence of the junction between EML4 exon 13 and ALK exon 20 in the S9 lesion, with an arrow indicating the junction.

Figure 3. Histological findings of the two lung lesions. H&E staining and immunohistochemistry with anti-L858R mutant EGFR specific antibody and anti-ALK antibody of lung lesions (S8/9 and S9) and mediastinal lymphnode metastasis are shown (10X objective).
Before alectinib 3M after alectinib initiation

CEA (ng/ml) 23.9 2.4

DISCUSSION

Three case reports (4-6) describe lung cancer patients with concomitant EGFR mutation and ALK translocation. However, it is unclear from these reports whether two tumors, each with one genetic alteration developed simultaneously, or a single tumor acquired both oncogenic drivers during its development. In our case, it is clear that two different lesions with different oncogenic drivers developed independently, because the microscopic appearance (lepidic vs papillary) and oncogenic drivers (EGFR mutation vs ALK translocation) were quite different in the surgically resected two tumors. This further indicates that double cancers with different oncogenic drivers can occur even in a young individual.

Recent clinical trials show the possibility of molecular diagnosis utilizing liquid biopsy specimens. However, it is still challenging in the clinical practice. Since our case did not have lesion for safe biopsy at the disease recurrence, we could not perform re-biopsy for assessing EGFR mutation and ALK translocation. We alternatively diagnosed that EML4-ALK component developed recurrent disease, because EML4-ALK component metastasized mediastinal and hilar lymph nodes at the surgical resection for double primary tumors. As the result, recurrent disease was dramatically diminished by alectinib treatment and controlled longer than 17 months. Our case also informed the importance of intensive molecular pathological diagnosis of surgical specimens for precision medicine by targeted drugs for recurrent disease.

CONFLICT OF INTERESTS-DISCLOSURE

Kengo Takeuchi received consulting fees from Nichirei Bioscience. Seiji Yano obtained speakers fees and research grant from Chugai Pharma. The other authors have nothing to disclose.

ACKNOWLEDGEMENTS

This case report is supported by Grant from the Project for Development of Innovative Research on Cancer Therapeutics from The Ministry of Education, Culture, Sports, Science and Technology of Japan (15cm0106062h0005).

REFERENCES


Figure 4. Effect of ALK inhibitor alectinib at the post-surgical recurrence. FDG-PET scan before and 3 months after the initiation of alectinib treatment (300 mg twice a day).